Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
42 studies found for:    CT-011
Show Display Options
RSS Create an RSS feed from your search for:
CT-011
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Condition: Lymphoma
Interventions: Drug: CT-011;   Drug: Rituximab
2 Completed Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: CT-011
3 Completed Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CT-011;   Drug: FOLFOX
4 Recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
5 Terminated Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
Condition: Chronic Hepatitis C
Intervention: Drug: CT-011
6 Terminated Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Condition: Primary Hepatocellular Carcinoma
Intervention: Drug: CT-011
7 Recruiting Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (Provenge);   Drug: Cyclophosphamide
8 Completed
Has Results
CT-011 MAb in DLBCL Patients Following ASCT
Conditions: Lymphoma, Large Cell, Diffuse;   Lymphoma, Mixed Cell, Diffuse;   Primary Mediastinal Large B-Cell Lymphoma
Intervention: Drug: CT-011
9 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
10 Withdrawn CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Conditions: Breast Cancer;   Colon Cancer;   Pancreatic Cancer;   Sarcoma;   Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide;   Drug: CT-011
11 Active, not recruiting PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Condition: Renal Cell Carcinoma
Interventions: Drug: CT-011;   Biological: DC/RCC fusion vaccine
12 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Conditions: Acute Myelogenous Leukemia;   AML
Interventions: Biological: DC AML Vaccine;   Drug: CT-011
13 Recruiting Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme
Condition: Malignant Gliomas
Intervention: Biological: CT-011
14 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Suspended Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies
Condition: Hyperlipoproteinemia Type I
Intervention:
16 Enrolling by invitation Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies
Condition: Lipoprotein Lipase Deficiency
Intervention:
17 Active, not recruiting A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
Conditions: Advanced Solid Tumor;   Lymphomas
Intervention: Drug: LEE011
18 Unknown  Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]
Condition: Familial Lipoprotein Lipase Deficiency
Interventions: Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X];   Drug: Mycophenolate mofetil;   Drug: cyclosporine
19 Completed Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects
Condition: Familial Lipoprotein Lipase Deficiency
Interventions: Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X];   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Drug: methylprednisolone
20 Completed Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)
Conditions: Renal Adverse Events - Contrast Induced Nephropathy (CIN);   Non-renal Adverse Events
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years